Canadian pharmaceutical firms Nuvo Research and Apotex have agreed a patent settlement allowing Apotex to launch a generic version of Nuvo’s arthritis treatment PENNSAID in the US in April 2014 or earlier under certain circumstances.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Nuvo Research, Apotex, PENNSAID, generics, patent settlement
